Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SW-682 en tumores sólidos avanzados

Un estudio de fase 1a / 1b de aumento y expansión de dosis de SW-682 en participantes con tumores sólidos avanzados enriquecidos para aquellos con mutaciones en la vía del hipopótamo

This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

186

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: US Medical Information
  • Número de teléfono: 888-275-7376
  • Correo electrónico: eMediUSA@emdserono.com

Ubicaciones de estudio

    • Arizona
      • Scottsdale, Arizona, Estados Unidos, 85258
        • Reclutamiento
        • HonorHealth Research Institute
        • Investigador principal:
          • Muhammad R Khawaja, MD
        • Contacto:
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • Reclutamiento
        • USC Norris Comprehensive Cancer Center and Hospital
        • Investigador principal:
          • Diana Hanna, MD
        • Contacto:
      • Sacramento, California, Estados Unidos, 92093
        • Reclutamiento
        • UC San Diego Moores Cancer Center
        • Investigador principal:
          • Sandip Patel, MD
        • Contacto:
      • Santa Monica, California, Estados Unidos, 90404
        • Reclutamiento
        • UCLA Hematology-Oncology - Santa Monica
        • Investigador principal:
          • Arun S Singh, MD
        • Contacto:
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Reclutamiento
        • University Hospital of Cleveland
        • Investigador principal:
          • Afshin Dowlati, MD
        • Contacto:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Reclutamiento
        • Oregon Health and Science University, Knight Cancer Institute - Marquam Hill
        • Investigador principal:
          • Shivaani Kummar
        • Contacto:
    • Texas
      • Dallas, Texas, Estados Unidos, 75230
        • Reclutamiento
        • Mary Crowley Research Center US Oncology
        • Investigador principal:
          • Douglas Orr, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • U.T. MD Anderson Cancer Center
        • Investigador principal:
          • Timothy Yap, MD
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

  • Histologically confirmed, metastatic, or unresectable solid cancer that has either not responded to or progressed during or after appropriate prior systemic anticancer therapy including chemotherapy, immunotherapy, radiation therapy, or appropriate targeted therapy, or for which there is no treatment available or prior SOC therapy was not tolerated and for which there is no further SOC treatment available

  • Part 1: must have one of the following:

    • Mesothelioma with or without NF2 mutations
    • Advanced solid tumors with NF2 mutations
    • Advanced solid tumors with other Hippo pathway mutations or fusions (e.g., FAT1, LATS1/2, YAP fusions; WWTR1-CAMTA1 in EHE).
  • Part 2: must have the tumor histology and oncogenic mutation or genomic aberration specific to each dose expansion cohort defined below:

    • Cohort 1: Participants with mesothelioma with or without NF2 mutations
    • Cohort 2: Participants with advanced solid tumors with NF2 mutations
    • Cohort 3: Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation
    • Cohort 4: SW-682 with appropriate combination therapy.
  • In both parts, participants should have known oncogenic mutation identified by Next Generation Sequencing or local assay

  • Must have archival tumor tissue or agree to a fresh tumor biopsy at screening

  • Measurable disease per RECIST 1.1

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1

  • Adequate bone marrow, kidney, hepatic, and coagulation function

Key Exclusion Criteria:

  • Evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression
  • Clinically significant cardiac disease or abnormal cardiac parameters
  • Preexistence or inheritance of a familial renal syndrome
  • Concomitant non-anti-arrhythmic medications that are known to prolong the QTc interval
  • Concomitant medicines that are known strong/moderate inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) and/or CYP1A2 within 14 days or 5 half-lives before the first dose of study treatment
  • Concomitant medicines that are known sensitive substrates of CYP3A4, CYP2C19, CYP2D6, CYP1A2, and/or CYP2B6 within 14 days or 5 half-lives before the first dose of study treatment
  • Concomitant medicines that are known sensitive substrates of PGP, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, OCT2
  • Clinically significant active infection (bacterial, fungal, or viral)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phase 1 Dose Escalation Cohorts Ranging in Dose

Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort.

SW-682 tablet administered orally

Experimental: Part 2 Dose Expansion Cohort 1

Participants with mesothelioma with or without NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.

SW-682 tablet administered orally

Experimental: Part 2 Dose Expansion Cohort 2

Participants with advanced solid tumors with NF2 mutations will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.

SW-682 tablet administered orally

Experimental: Part 2 Dose Expansion Cohort 3

Participants with advanced solid tumors with other Hippo pathway mutations identified during Part 1 (Phase 1a) dose escalation will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data.

SW-682 tablet administered orally

Experimental: Part 2 Dose Expansion Cohort 4

Participants will receive SW-682 tablets administered orally in continuous 28-day cycles at the recommended dose for expansion, based on Part 1 data, with appropriate combination therapy, identified based on Part 1 data.

SW-682 tablet administered orally

Appropriate combination therapy

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Adverse Events (Part 1 Only)
Periodo de tiempo: Up to 24 months

Safety and tolerability endpoint evaluation via incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment emergent adverse events (TEAE)

Up to 24 months
Maximum Tolerated Dose (Part 1 Only)
Periodo de tiempo: Up to 24 months

The maximum tolerated dose (MTD) for SW-682, if any, will be based on safety and tolerability during the first 28 days of treatment in Cycle 1.

Up to 24 months
Recommended Dose for Expansion (Part 1 Only)
Periodo de tiempo: Up to 24 months

The recommended dose for expansion (RDE) will be determined based on all safety, tolerability, pharmacokinetics (PK), preliminary antitumor efficacy, and other available data from Part 1 of the study.

Up to 24 months
Objective Response Rate (Part 2 Only)
Periodo de tiempo: Up to 24 months

Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator.

Up to 24 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in plasma and urine concentrations of SW-682
Periodo de tiempo: Up to 24 months

Plasma and urine concentrations of SW-682 and any relevant metabolite(s) will be measured to evaluate systemic exposures and renal elimination.

Up to 24 months
Objective Response Rate (Part 1 Only)
Periodo de tiempo: Up to 24 months

Objective response rate (ORR), defined as the proportion of participants with confirmed CR or PR using RECIST v1.1, mRECIST for mesothelioma, and/or GCIG CA-125 for ovarian cancer, as applicable, assessed by the investigator.

Up to 24 months
Disease Control Rate
Periodo de tiempo: Up to 24 months

Disease control rate (DCR), defined as the percentage of participants with CR, PR, or stable disease (SD) after starting study treatment.

Up to 24 months
Duration of Response
Periodo de tiempo: Up to 24 months

Duration of response (DoR), defined as the time from response (CR + PR using RECIST v1.1, mRECIST and/or (GCIG) criteria for CA-125 response in ovarian cancer, as applicable) to disease progression and/or death, whichever occurs first.

Up to 24 months
Progression-Free Survival
Periodo de tiempo: Up to 24 months

Progression-free survival (PFS), defined as the time from the date of the first administration of study treatment to the first documented disease progression per RECIST v1.1, mRECIST, and/or GCIG CA-125, as applicable, or death due to any cause, whichever occurs first.

Up to 24 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Medical Responsible, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de julio de 2024

Finalización primaria (Estimado)

18 de enero de 2027

Finalización del estudio (Estimado)

18 de enero de 2027

Fechas de registro del estudio

Enviado por primera vez

1 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

1 de febrero de 2024

Publicado por primera vez (Actual)

9 de febrero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir